Incyte Completes Acquisition of Escient Pharmaceuticals
Key Highlights Incyte acquires Escient Pharmaceuticals for $750 million plus net cash. Acquisition includes EP262 and EP547, first-in-class MRGPR antagonists. Enhances Incyte’s Inflammation and Autoimmunity portfolio. Potential treatments…
